Skip to main content
. 2021 May 12;13(10):2312. doi: 10.3390/cancers13102312

Figure 5.

Figure 5

Kaplan-Meier plot illustrating the progression-free survival separated by the reasons for treatment discontinuation. Patients who terminated BRAF ± MEKi therapy due to toxicity or disease progression had a significantly shorter PFS (median PFS: 3 months vs. 10 months) compared to patients with ongoing treatment (median PFS not reached, p < 0.0001) or treatment discontinuation due to other reasons (termed as physician’s choice) (median PFS: 40 months, p = 0.013).